News & Events
Insight Genetics announced the promotion of David Hout, PhD, to vice president of research and development. Hout led development of the cancer diagnostic firm’s two tests, Insight ALK Screen™ and Insight ALK Resistance™, which together advance personalized cancer care by enabling diagnosis of and therapy for ALK-driven cancers. Insight also added Brock Schweitzer, PhD, and Kasey Lawrence to its research team as scientist II and research associate III, respectively.
Eric Dahlhauser, chairman and CEO of molecular diagnostics company Insight Genetics, discusses the company’s development and marketing of genetic tests to guide targeted therapy for certain cancers.
The strategic co-development partnership and licensing agreement with Insight Genetics gives QIAGEN worldwide exclusive rights to Insight Genetics' diagnostic IP to the ALK gene. The companies will collaborate in the development of a corresponding test that can be clinically validated and marketed by QIAGEN as a companion diagnostic.
QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Insight Genetics has entered into a strategic co-development partnership and licensing agreement with QIAGEN for a genetic test covering the ALK (anaplastic lymphoma kinase) biomarker, a promising target for a novel class of lung cancer drugs.
Cancer diagnostics firm Insight Genetics today announced that it has received a $193,000 Small Business Innovation Research contract from the National Cancer Institute (NCI) to develop a companion diagnostic test for drugs targeting mutations and fusions of anaplastic lymphoma kinase (ALK). The test, Insight ALK Resistance™, is being developed to meet a growing challenge within personalized cancer care: the development of tumor resistance to a prescribed drug.